Showing 1,532 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

Major Win for Patients as Brazil Rejects A Key Patent on Gilead Hepatitis C Drug and European Union Denies Patent Extension to Gilead’s HIV Drug

Editor's pick
I-MAK
8 May 2018
Pharmaceutical industry

Gilead Topples As Its Hepatitis C Drug Franchise Continues To Crumble

Editor's pick
Investor's Business Daily
2 May 2018
Pharmaceutical industry

GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth

Editor's pick
FiercePharma
30 April 2018
New & experimental HIV treatments

European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

Editor's pick
Gilead press release
27 April 2018
Pharmaceutical industry

Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback?

Editor's pick
Washington Post
10 April 2018
Clinical trials

My PrEP story: Patrick (part 2)

Editor's pick
Prepster
10 April 2018
Pharmaceutical industry

Why do new medicines cost so much, and what can we do about it?

Editor's pick
The Guardian
10 April 2018
Pharmaceutical industry

A Cheaper Version of Truvada Is Hitting the US Market: Here's Why It Might Not Lower Costs

Editor's pick
The Body
4 April 2018
Pharmaceutical industry

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S.

Editor's pick
Mylan press release
3 April 2018
New & experimental HIV treatments

ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

Editor's pick
ViiV press release
23 March 2018
Pharmaceutical industry

Argentine NGO objects to antiretroviral patent request

Editor's pick
Sci Dev Net
23 March 2018
Pharmaceutical industry

Gilead Sciences: The Future Is Complicated

Editor's pick
Seeking Alpha
14 March 2018
Drug-resistant TB

J&J, Macleods in talks for licence deal of tuberculosis drug

Editor's pick
Economic Times
13 March 2018
Pharmaceutical industry

Two new generic HIV regimens to be introduced in US

Editor's pick
Healio
6 March 2018
Pharmaceutical industry

Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

Editor's pick
Nasdaq
19 February 2018
New & experimental HIV treatments

ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

Editor's pick
ViiV press release
8 February 2018
New & experimental HIV treatments

US FDA approves Gilead triple HIV drug, rival files lawsuit

Editor's pick
Reuters
8 February 2018
Pharmaceutical industry

Janssen HIV Drug U.K. Patent Extension Case to Go to EU Top Court

Editor's pick
Bloomberg
7 February 2018
PEP

Activists Demand Gilead Rescind nPEP Patient Access Program's Once-Per-Lifetime Use Limit

Editor's pick
The Body
2 February 2018
Pharmaceutical industry

GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay

Editor's pick
Market Realist
1 February 2018
Hepatitis C treatment

NHS England seeks drug price cuts to eliminate hepatitis C by 2025

News
30 January 2018
Pharmaceutical industry

Brexit could leave patients unable to access new drugs

Editor's pick
The Guardian
30 January 2018
Pharmaceutical industry

Teva Announces Exclusive Launch of a Generic Version of Reyataz® in the United States

Editor's pick
Teva press release
10 January 2018
Pharmaceutical industry

Brexit: Fears of disruption to flow of medicines means UK must stay under EU regulation, say government figures

Editor's pick
The Independent
9 January 2018